- Home
- SEER
SEER
Seer Inc.
as 12-18-2024 9:42am EST
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 143.3M | IPO Year: | 2020 |
| Target Price: | $3.00 | AVG Volume (30 days): | 214.1K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.51 - $2.63 | Next Earning Date: | 11-06-2024 |
| Revenue: | $14,608,000 | Revenue Growth: | -13.19% |
| Revenue Growth (this year): | -13.56% | Revenue Growth (next year): | 34.78% |
Latest Seer Inc. News
SEER Breaking Stock News: Dive into SEER Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Simply Wall St.
a month ago
Seer Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
a month ago
Seer to Participate in Upcoming November Investor Conferences
GuruFocus.com
a month ago
Seer Inc (SEER) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...
Zacks
a month ago
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Seer Reports Third Quarter 2024 Financial Results
GlobeNewswire
a month ago
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
GuruFocus.com
a month ago
Earnings To Watch: Seer Inc (SEER) Reports Q3 2024 Result
Compare SEER vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SEER Seer Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.